JCR Pharmaceuticals Co., Ltd.
JCRRF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.68 | -0.61 | 0.17 |
| FCF Yield | -18.12% | 4.22% | -8.19% | -0.76% |
| EV / EBITDA | -38.05 | 16.68 | 24.30 | 12.04 |
| Quality | ||||
| ROIC | -5.60% | 7.11% | 4.55% | 21.24% |
| Gross Margin | 65.73% | 72.90% | 74.13% | 79.52% |
| Cash Conversion Ratio | 0.86 | 1.69 | -1.02 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.25% | -5.67% | 4.51% | 27.27% |
| Free Cash Flow Growth | -313.02% | 151.33% | -587.87% | -172.64% |
| Safety | ||||
| Net Debt / EBITDA | -8.63 | 0.43 | 1.28 | -0.59 |
| Interest Coverage | -42.90 | 87.58 | 113.07 | 442.96 |
| Efficiency | ||||
| Inventory Turnover | 0.52 | 0.56 | 0.48 | 0.71 |
| Cash Conversion Cycle | 816.80 | 756.72 | 814.64 | 575.84 |